Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SinoMab is Raising $223 Million in a Hong Kong IPO

publication date: Oct 31, 2019

SinoMab Bioscience, a Hong Kong company that develops antibodies and immunotherapies for autoimmune diseases and cancer, will raise up to $223 million in a Hong Kong IPO. The company’s lead candidate, SM03, is a global first-in-class mAb that is currently in a China Phase III trial for rheumatoid arthritis. SM03 targets CD22, a novel antigen found only on B cells. SinoMab expects to submit an NDA for SM03 by mid-2020. SinoMab began offering shares today and will continue until November 5, with trading starting on November 6. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital